Seaport Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPTX research report →
Range $30 – $50
Price Chart
About the company
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology.
- CEO
- Daphne Zohar
- IPO
- 2026
- Employees
- 58
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on SPTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $929.83M
- P/E
- -10.53
- PEG
- -0.11
- P/S
- 0.00
- P/B
- 2.20
- EV/EBITDA
- -9.40
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -57.34%
- ROIC
- -21.83%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-87,294,000
- Net Income
- $-74,881,000+0.0%
- EPS
- $-1.94+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $28.38
- 52W Low
- $14.85
- 50D MA
- $22.54
- 200D MA
- $20.36
- Beta
- 1.13
- RSI (14)
- 34
- Avg Volume
- 180.45K
No earnings-call transcripts are available for SPTX yet.
- Free Float
- 32.7%
- Shares Outstanding
- 53.53M
- Float Shares
- 17.51M
of shares held by institutions
56 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Arch Venture Management, LLC | 6.29M | ▲ 6.29M |
| General Atlantic, L.P. | 6.10M | ▲ 6.10M |
| Sofinnova Investments, Inc. | 3.56M | ▲ 3.56M |
| Goldman Sachs Group Inc | 2.18M | ▲ 2.18M |
| Trv Gp Vi, LLC | 2.06M | ▲ 2.06M |
| Canada Pension Plan Investment Board | 1.98M | ▲ 1.98M |
| Jpmorgan Chase & Co | 1.82M | ▲ 1.82M |
| Foresite Capital Management Vi LLC | 1.78M | ▲ 1.78M |
| Price T Rowe Associates Inc | 1.31M | ▲ 1.31M |
| Fmr LLC | 1.19M | ▲ 1.19M |
| Bellevue Group AG | 1.10M | ▲ 1.10M |
| Siren, L.L.C. | 1.10M | ▲ 1.10M |
Held by 74 ETFs
Biggest fund positions in SPTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | PureTech Health plc | other | 965,255 |
| May 4, 26 | PureTech Health plc | other | 2,681,265 |
| May 4, 26 | PureTech Health plc | other | 12,736,014 |
| May 4, 26 | PureTech Health plc | other | 3,031,578 |
| May 4, 26 | PureTech Health plc | other | 40,000,000 |
| May 4, 26 | PureTech Health plc | other | 8,421,052 |
| Apr 30, 26 | PureTech Health plc | other | 0 |
| Apr 30, 26 | PureTech Health plc | other | 12,736,014 |
| Apr 30, 26 | PureTech Health plc | other | 2,681,265 |
| Apr 30, 26 | PureTech Health plc | other | 965,255 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SPTX coverage
Recent articles, reports, and earnings notes.
No research on SPTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPTX report →Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
businesswire.com · Oct 7
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up – Should You Buy?
defenseworld.net · Oct 3
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Down – What’s Next?
defenseworld.net · Oct 2
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57
defenseworld.net · Sep 28
Seaport Therapeutics to Participate in September Investor Conferences
businesswire.com · Sep 14
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com · Sep 9
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
gurufocus.com · Sep 9
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
businesswire.com · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.